BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36142631)

  • 21. Blue lacy matrix in giant cell tumour of bone with or without denosumab therapy.
    Toda Y; Ishihara S; Kawai A; Yoshida A
    Virchows Arch; 2023 Jul; 483(1):125-129. PubMed ID: 36447097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases.
    Leinauer B; Wolf E; Werner M; Baumhoer D; Breining T; Luebke AM; Maas R; Schultheiß M; von Baer A; Sufi-Siavach A; Moritz C; Geißler S; Mellert K; Möller P; Barth TFE; Jundt G
    Histopathology; 2021 Nov; 79(5):720-730. PubMed ID: 33991114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiological Assessment of Giant Cell Tumour of Bone in the Sacrum: From Diagnosis to Treatment Response Evaluation.
    Langevelde KV; Vucht NV; Tsukamoto S; Mavrogenis AF; Errani C
    Curr Med Imaging; 2022; 18(2):162-169. PubMed ID: 33845749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updated concepts in treatment of giant cell tumor of bone.
    van der Heijden L; Lipplaa A; van Langevelde K; Bovée JVMG; van de Sande MAJ; Gelderblom H
    Curr Opin Oncol; 2022 Jul; 34(4):371-378. PubMed ID: 35837707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
    Rutkowski P; Gaston L; Borkowska A; Stacchiotti S; Gelderblom H; Baldi GG; Palmerini E; Casali P; Gronchi A; Parry M; Campanacci DA; Scoccianti G; Wagrodzki M; Ferrari S; Dijkstra S; Pieńkowski A; Grimer R
    Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1.
    Okubo T; Saito T; Mitomi H; Takagi T; Torigoe T; Suehara Y; Kaneko K; Yao T
    Virchows Arch; 2013 Jul; 463(1):67-77. PubMed ID: 23748877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Giant cell tumor of bone: current treatment options.
    Skubitz KM
    Curr Treat Options Oncol; 2014 Sep; 15(3):507-18. PubMed ID: 24788576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant Sarcomatous Transformation of Benign Giant Cell Tumor of Bone after Treatment with Denosumab Therapy: A Literature Review of Reported Cases.
    Alaqaili SI; Abduljabbar AM; Altaho AJ; Khan AA; Alherabi JA
    Cureus; 2018 Dec; 10(12):e3792. PubMed ID: 30868006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.
    Raimondi A; Simeone N; Guzzo M; Maniezzo M; Collini P; Morosi C; Greco FG; Frezza AM; Casali PG; Stacchiotti S
    ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32661185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
    J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
    Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Utility of Genetic and Immunohistochemical
    Wągrodzki M; Tysarowski A; Seliga K; Wojnowska A; Stepaniuk M; Castañeda Wysocka P; Makuła D; Pieńkowski A; Szostakowski B; Zub R; Rutkowski P
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Giant Cell Tumor of Bone Without Giant Cells with a Long Clinical Course: A Case Report.
    Takase H; Kato I; Ito J; Kawabata Y; Okabe T; Takeyama M; Fujii S
    Int J Surg Pathol; 2023 Apr; 31(2):190-194. PubMed ID: 35502834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
    Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
    BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-Histone H3.3 G34W antibody is a sensitive and highly specific immunohistochemistry marker for the diagnosis of Giant cell tumor of bone. A validation based on analysis of 198 cases from a single centre in India.
    Kamble A; Hui M; Rao KN; Narayanan R; Reddy BR; Uppin SG; Chandrasekhar P
    Indian J Pathol Microbiol; 2022; 65(3):617-629. PubMed ID: 35900490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic giant cell tumour of bone: a narrative review of management options and approaches.
    Xu R; Choong PFM
    ANZ J Surg; 2022 Apr; 92(4):691-696. PubMed ID: 35143093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological Features of a Series of 27 Cases of Post-Denosumab Treated Giant Cell Tumors of Bones: A Single Institutional Experience at a Tertiary Cancer Referral Centre, India.
    Rekhi B; Verma V; Gulia A; Jambhekar NA; Desai S; Juvekar SL; Bajpai J; Puri A
    Pathol Oncol Res; 2017 Jan; 23(1):157-164. PubMed ID: 27722984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.
    Amary F; Berisha F; Ye H; Gupta M; Gutteridge A; Baumhoer D; Gibbons R; Tirabosco R; O'Donnell P; Flanagan AM
    Am J Surg Pathol; 2017 Aug; 41(8):1059-1068. PubMed ID: 28505000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone.
    Balla P; Maros ME; Barna G; Antal I; Papp G; Sapi Z; Athanasou NA; Benassi MS; Picci P; Krenacs T
    PLoS One; 2015; 10(5):e0125316. PubMed ID: 25933380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.